A Pharmacokinetic Study Evaluating the Relationship Between Treatment Efficacy and Incidence of Adverse Events with Thalidomide Plasma Concentrations in Patients with Refractory Multiple Myeloma-Reference-Cited by-同舟云学术

A Pharmacokinetic Study Evaluating the Relationship Between Treatment Efficacy and Incidence of Adverse Events with Thalidomide Plasma Concentrations in Patients with Refractory Multiple Myeloma

Published:2009-04 Issue:2 Volume:9 Page:154-159
ISSN:1557-9190
Container-title:Clinical Lymphoma and Myeloma
language:en
Short-container-title:Clinical Lymphoma and Myeloma

Author:

Kodama Tomoko,Abe Masahiro,Iida Shinsuke,Ozaki Shuji,Sakai Akira,Sawamura Morio,Shimazaki Chihiro,Miyata Akira,Wakayama Toshio,Murakami Hirokazu

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology,General Medicine

Reference28 articles.

1. Single versus double autologous stem-cell transplantation for multiple myeloma;Attal;N Engl J Med,2003

2. Thalidomide embryopathy in Germany, 1959-1961;Lenz;Prog Clin Biol Res,1985

3. Thalidomide metabolism in mice and patients with multiple myeloma;Lu;Clin Cancer Res,2003

4. Thalidomide metabolism by the CYP2C subfamily;Ando;Clin Cancer Res,2002

5. Thalidomide is an inhibitor of angiogenesis;D'Amato;Proc Natl Acad Sci U S A,1994

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Establishment of a novel non-integrated human pluripotent stem cell-based gastruloid model;2023-06-28

2. Thalidomide measurement in plasma and dried plasma spot by SPE combined with UHPLC-MS/MS for therapeutic drug monitoring;Bioanalysis;2022-08

3. A novel human stem cell‐based biomarker assay for in vitro assessment of developmental toxicity;Birth Defects Research;2022-03-14

4. One-year prospective nerve conduction study of thalidomide neuropathy in lupus erythematosus: Incidence, coasting effect and drug plasma levels;Lupus;2021-03-03

5. A novel human pluripotent stem cell-based assay to predict developmental toxicity;Archives of Toxicology;2020-07-22